Delivering the next generation gene therapies

Our mission

Gene Therapy based on Adeno-Associated Viral (AAV) vectors has proven effective for several forms of genetic blindness, however the small vector payload may limit their further application. The company develops two AAV-based platforms with expanded transfer capability that enable the delivery of large genes.

About us

AAVantgarde is an innovative biotech start-up, co-founded by Dr. Alberto Auricchio and originating from research activities performed at Tigem (Telethon Institute of Genetics and Medicine) in Naples, Italy, and backed by Sofinnova Partners.